As demonstrated in Fig. 1D lower panel, patients with higher ALDOB levels in their tumor tissue exhibited poorer therapeutic outcomes, suggesting that ALDOB expression affects the sensitivity of CRC cells to 5-FU or oxaliplatin. Here, ALDOB is linked to neoplasm.